Rivastigmine Tartrate
50 NDCs across 10 manufacturers|50 Generic,0 Brand
Rivastigmine Tartrate is used to treat alzheimer disease, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Apr 21, 2000, and the first generic was approved Oct 22, 2007. FDA's Orange Book lists 32 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $20 million on Rivastigmine Tartrate across 355,000 claims for 63,000 beneficiaries.
Rivastigmine Tartrate is available as 50 NDCs from 10 manufacturers (50 generic, 0 brand), with NADAC prices from $0.15 to $0.37 per EA — the most expensive product costs about 2.5× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
50
50G / 0B
Manufacturers
10
competing in market
Price Spread
$0.15 – $0.37
per EA
7d Activity
avg -0.9% WoW · of 50 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Nivagen Pharmaceuticals Inc. manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Cholinesterase Inhibitor class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
10 manufacturers producing RIVASTIGMINE TARTRATE(2 pricing outliers)
Frequently Asked Questions
What is Rivastigmine Tartrate used to treat?
Rivastigmine Tartrate is used to treat alzheimer disease, per the National Library of Medicine's MED-RT classification.
When did Rivastigmine Tartrate become available as a generic?
FDA approved the first generic Rivastigmine Tartrate (ANDA) on Oct 22, 2007. The Orange Book currently lists 32 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Rivastigmine Tartrate?
In 2024, Medicare Part D spent $20 million on Rivastigmine Tartrate across 355,000 claims for 63,000 beneficiaries.
How many Rivastigmine Tartrate products are on the market?
The Rivastigmine Tartrate drug market contains 50 NDCs from 10 manufacturers — 50 generic and 0 brand products.
What is the price range for Rivastigmine Tartrate?
NADAC reference prices for Rivastigmine Tartrate range from $0.1458 to $0.3653 per EA — the most expensive product costs about 2.5× the cheapest.
Which manufacturers make Rivastigmine Tartrate?
10 manufacturers list Rivastigmine Tartrate in NADAC. Ranked by number of NDCs, the largest are Nivagen Pharmaceuticals Inc. (8), Sun Pharmaceutical Industries Inc. (8), Dr. Reddy's Laboratories Inc. (8), Macleods Pharmaceuticals Limited (8), Alembic Pharmaceuticals Inc. (4).
How has the price of Rivastigmine Tartrate changed recently?
Over the past 7 days, 18 Rivastigmine Tartrate NDCs rose and 16 fell, with a market-wide average change of -0.9%.